<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The pathophysiology of <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> was studied by investigating the metabolism of the drug <z:chebi fb="0" ids="27999">tolbutamide</z:chebi>, which is metabolised by the liver but does not undergo glucuronidation </plain></SENT>
<SENT sid="1" pm="."><plain>Using rat liver cell supernatant, <z:chebi fb="0" ids="27999">tolbutamide</z:chebi> was shown to bind to the hepatic cytoplasmic Y protein in a manner similar to other <z:chebi fb="0" ids="25696">organic anions</z:chebi>, but not to Z protein </plain></SENT>
<SENT sid="2" pm="."><plain>In 31 patients with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> the plasma disappearance (plasma half-life, mean +/- SD: 628+/-84 min) and metabolic clearance (7-9+/-1-8 ml/min) were significantly (P less than 0-0005) altered compared with the 13 controls (mean half-life 393+/-26 and mean clearance 13-4+/-1-5) </plain></SENT>
<SENT sid="3" pm="."><plain>The eight patients with <z:e sem="disease" ids="C0020433" disease_type="Disease or Syndrome" abbrv="">hyperbilirubinaemia</z:e> due to <z:e sem="disease" ids="C1263988" disease_type="Disease or Syndrome" abbrv="">haemolytic disease</z:e> showed no difference from the <z:mpath ids='MPATH_458'>normal</z:mpath> control subjects </plain></SENT>
<SENT sid="4" pm="."><plain>In three patients with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> the cumulative urinary excretion of <z:chebi fb="0" ids="27999">tolbutamide</z:chebi> metabolites, 24 hours after the administration of the drug, was 30% lower than in the controls </plain></SENT>
<SENT sid="5" pm="."><plain>In the five patients with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e>, <z:chebi fb="1" ids="8069">phenobarbital</z:chebi> administration (100 mg/day) produced a significant increase in clearance of the drug from 8-8+/-0-8 to 13-4+/-1-9 ml/min; this was paralleled by a fall in serum <z:chebi fb="0" ids="16990">bilirubin</z:chebi> concentration </plain></SENT>
<SENT sid="6" pm="."><plain>The plasma half-life of <z:chebi fb="0" ids="27999">tolbutamide</z:chebi> was similar in Gunn rats and Wistar rats </plain></SENT>
<SENT sid="7" pm="."><plain>The results suggest that the metabolic defect(s) of <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> affects compounds other than <z:chebi fb="0" ids="16990">bilirubin</z:chebi> and that defective uptake is probably the major factor </plain></SENT>
</text></document>